Pharmaceuticals

A potential first-ever treatment for a severe rare skin disease gets a major boost from the FDA, accelerating its path to patients and exciting investors.

SciTech's ST-001 overcomes a decades-old barrier for fenretinide, showing promising results for Cutaneous T-Cell Lymphoma patients in early trials.

With CE Mark approval, Countable Labs brings single-molecule counting PCR to Europe, promising unprecedented precision for gene therapy and diagnostics.

Following a 40-year career shaping biotech finance, Jessica Chutter's move to PTC's board signals major strategic ambitions for the rare disease firm.

Biolojic Design's adaptive AI drug for asthma and eczema hits a key milestone with Teva, heralding a new era for personalized autoimmune treatment.

From the heart of Arabia, AlUla Peregrina brings a patented active to the global stage, promising scientifically-backed, ethical longevity beauty.

Venture capital leaders and national security experts caution that drug pricing controls and regulatory hurdles could cede America's biomedical edge to rivals.

Sequoia Group launches 'Pages,' a collaborative workspace, and its 2026 report to help firms navigate rising costs, AI talent wars, and compensation.

With a top expert at the helm, AltaThera aims to expand its heart rhythm drug for kids, balancing life-saving potential with critical safety warnings.

US brands hit a record $6.44T value, led by tech titans. But as corporate power grows, America's global reputation is in a steep, historic decline.

The PBM is launching new solutions that challenge traditional pricing models with predictable costs and integrated patient support for obesity care.

Apimeds Pharmaceuticals accuses its Korean partner of an illegal board seizure, sparking a high-stakes legal fight in Delaware and Seoul over a broken merger.

Experic and Flurry Powders form a strategic alliance to accelerate complex therapies by combining advanced particle engineering with GMP manufacturing.

With new financing from Avenue Capital, Turn Therapeutics bets big on its novel skin therapy, GX-03, to tackle multi-billion dollar dermatology markets.

A US-Japan biotech firm secures major funding to advance a first-in-class drug, offering new hope for millions with inherited blood disorders.

Cipla Health launches a Masala Guava flavored ORS, targeting India's daily wellness market by turning a medical staple into an enjoyable hydration choice.

The CRDMO giant posted a 16.7% revenue jump in 2025, driven by a massive pipeline expansion and a strategic pivot to next-generation biologics.

RA Capital's major investment extends Karyopharm's runway, but future funding is now directly tied to the outcome of its pivotal endometrial cancer trial.

Merck's breakthrough PAH drug is now covered in several provinces, offering new hope. But what about its high cost and access for the rest of Canada?

Investors eye Cardinal Health's April 30 report for signs its aggressive diversification and specialty pharma push can sustain its powerful earnings momentum.